BioMarin Pharmaceutical
Update in progressBMRN (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing therapies for rare, life-threatening diseases worldwide. Its approved products include VIMIZIM for MPS IV type A, VOXZOGO for achondroplasia, NAGLAZYME for MPS VI, PALYNZIQ to reduce blood phenylalanine, BRINEURA for Batten disease, ALDURAZYME for alpha-L-iduronidase deficiency, and KUVAN for phenylketonuria. It develops BMN 333 and BMN 351 and is headquartered in San Rafael, California.
Company score
- Sentiment
- 1.08
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- -0.24
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.78
- Governance
- 0.34
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.22
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.65
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Alexander Hardy
- Founded1996
- Employees3,221
- Websitewww.biomarin.com
Identifiers
- ISINUS09061G1013
- FIGIBBG000CZWZ05
- LEINSLL8ITTRR0J5HEMR848
- CUSIP09061G101
- CIK0001048477